Bristol-Myers Squibb Company (BMY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 43 | 46 | 46 | 45 | 48 | 48 | 49 | 50 |
| Operating profit | $bn | 14 | 14 | ||||||
| Net profit | $bn | -9 | 7 | 6 | 8 | -9 | 7 | 9 | 14 |
| EPS reported | $ | 3.45 | 4.54 | ||||||
| Operating cashflow per share | $ | 6.94 | 6.26 | ||||||
| Capex per share | $ | 0.64 | 0.66 | ||||||
| FCF per share | $ | 6.29 | 5.60 | ||||||
| Free cash flow | $bn | 13 | 11 | ||||||
| Net debt | $bn | 34 | 32 | ||||||
| Book value equity | $bn | 18 | 22 | ||||||
| Book value per share | $ | 9.05 | 10.90 | ||||||
| Number of shares | m | 2,041 | 2,048 | ||||||
| DPS (TTM paid) | $ | 2.48 | 3.14 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 15.63 | 13.85 | ||||||
| P/B LTM | x | 5.96 | 4.93 | ||||||
| P/S LTM | x | 2.28 | 2.24 | ||||||
| P/FCF LTM | x | 8.57 | 9.62 | ||||||
| EV/EBITDA LTM | x | 9.65 | 8.82 | ||||||
| EV/Sales LTM | x | 3.05 | 3.47 | ||||||
| Earnings Yield LTM | % | +6.40% | +7.22% | ||||||
| FCF Yield | % | +11.67% | +10.39% | ||||||
| Quality | |||||||||
| ROE | % | +38.19% | +46.75% | ||||||
| ROIC | % | +15.03% | +15.47% | ||||||
| Operating margin | % | +28.48% | +28.27% | ||||||
| Gross margin | % | +71.08% | +70.16% | ||||||
| FCF/Sales | % | +26.65% | +23.26% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -0.22% | +1.84% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -7.87% | -17.95% | ||||||
| Operating Profit Growth | % | +42.10% | +43.95% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +4.58% | +3.76% | ||||||
| Dividend Growth | % | +3.33% | +30.83% | ||||||
| Payout Ratio | % | +71.65% | +54.94% | ||||||
| FCF/Debt | x | 0.27 | 0.27 | ||||||
| Net Debt/EBITDA | x | 2.42 | 2.06 | ||||||
| EBIT/Net interest | x | 7.26 | 8.04 | ||||||
| Net debt/market cap | % | +40.98% | +31.59% | ||||||
| Net debt/Equity | x | 1.86 | 1.44 | ||||||
| Gross debt/equity | x | 2.55 | 1.93 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free